Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sanara MedTech Inc. before investing.

In this article, we go over a few key elements for understanding Sanara MedTech Inc.’s stock price such as:

• Sanara MedTech Inc.’s current stock price and volume
• Why Sanara MedTech Inc.’s stock price changed recently
• Upgrades and downgrades for SMTI from analysts
• SMTI’s stock price momentum as measured by its relative strength

About Sanara MedTech Inc. (SMTI)

Before we jump into Sanara MedTech Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Want to learn more about Sanara MedTech Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sanara MedTech Inc..

Sanara MedTech Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Sanara MedTech Inc.’s stock price was $33.860.

Sanara MedTech Inc. is down 0.59% from its previous closing price of $34.060.

During the last market session, Sanara MedTech Inc.’s stock traded between $33.620 and $34.000. Currently, there are approximately 8.71 million shares outstanding for Sanara MedTech Inc..

Sanara MedTech Inc.’s price-earnings (P/E) ratio is currently at 513.0, which is high compared to the Health Care Equipment & Supplies industry median of 31.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Sanara MedTech Inc. Stock Price History

Sanara MedTech Inc.’s (SMTI) price is currently up 43.54% so far this month.

During the month of July, Sanara MedTech Inc.’s stock price has reached a high of $34.250 and a low of $23.000.

Over the last year, Sanara MedTech Inc. has hit prices as high as $35.950 and as low as $16.047. Year to date, Sanara MedTech Inc.’s stock is up 45.01%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Sanara MedTech Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Sanara MedTech Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Sanara MedTech Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sanara MedTech Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Sanara MedTech Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sanara MedTech Inc. (SMTI) by visiting AAII Stock Evaluator.

Relative Price Strength of Sanara MedTech Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Sanara MedTech Inc. has a weighted four-quarter relative price strength of 20.70%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Sanara MedTech Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sanara MedTech Inc. Stock Price: Bottom Line

As of July 31, 2026, Sanara MedTech Inc.’s stock price is $33.860, which is down 0.59% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sanara MedTech Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.